New light shed on VTE prophylaxis in medical patients

The current state of the art

9 July 2019, 13:15–14:30, Meeting Room 109/110
Chair: Grégoire Le Gal (Ottawa, Canada)
New light shed on VTE prophylaxis in medical patients

The current state of the art

13:15 Welcome and introduction

13:20 The current landscape, advances and challenges for VTE prophylaxis in medically ill patients
   Grégoire Le Gal

13:35 Residual risk: Considerations for optimizing VTE prophylaxis in post-discharge patients with medical illness
   Ana Rocha

13:55 Risk-benefit adjusted VTE prophylaxis in medical patients with cancer
   Andres Muñoz

14:15 Q&A

14:25 Conclusion & Take home messages

In Australia, Clexane/Lovenox is indicated as prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. Please review Product Information before prescribing. The Product Information can be accessed at http://www.guildlink.com.au/gc/ws/sw/pi.cfm?product=swpclexa10718

Grégoire Le Gal
Ottawa, Canada

Ana Rocha
Salvador de Bahia, Brazil

Andres Muñoz
Madrid, Spain